US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi U.S. Biotech 2x Daily ETF

34.21

-0.1504-0.44%

Post-market: 34.950.7361+2.15%16:10 EDT

Volume:15.63K

Turnover:546.62K

Market Cap:513.21K

PE:- -

High:34.99

Open:34.99

Low:34.21

Close:34.36

52wk High:42.22

52wk Low:25.26

Shares:15.00K

Float Shares:15.00K

Volume Ratio:5.10

T/O Rate:104.17%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

ASX biotech expands diagnostics portfolio after FDA approval

Morning Star AU

AdAlta takes ‘East to West’ CAR-T strategy and EW-001 data to U.S. investors

Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803

Noxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market

The Race for the Next Big Weight-Loss Drug is On-and China Wants In

Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding

Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs

Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement

VOOLT launches deeptech strategy with co‑investment in biotech firm Pikralida

PegBio Partners SN BioScience to Advance Long-Acting Metabolic Peptide Candidates

BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics

FutureChem sets final issue price for paid-in capital increase

Vogenx initiated with a Buy at Jones

Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative

Simply Wall St.

NeuroThera Labs Hires European IR Firm to Expand Investor Reach

Oppenheimer biotech analysts hold an analyst/industry conference call

Natera and Angiex partner in tumor testing using Signatera

Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs

4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing

Syngenis banks R&D refund to fuel biotech build-out

The West Australian

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/XBIX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"XBIX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBIX\",,,,,undefined,":{"symbol":"XBIX","market":"US","secType":"STK","nameCN":"Corgi U.S. Biotech 2x Daily ETF","latestPrice":34.2139,"timestamp":1790971200000,"preClose":34.3643,"halted":0,"volume":15626,"hourTrading":{"tag":"盘后","latestPrice":34.95,"preClose":34.2139,"latestTime":"16:10 EDT","volume":4,"amount":136.8556,"timestamp":1790971805190,"change":0.7361,"changeRate":0.021515,"amplitude":0},"delay":0,"changeRate":-0.00437663505440232,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"Market Closed","change":-0.1504,"latestTime":"10-02 16:00:00 EDT","open":34.99,"high":34.99,"low":34.2139,"amount":546621,"amplitude":0.022584,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":34.3643,"nav":34.28,"aum":514200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.95,"preClose":34.2139,"latestTime":"16:10 EDT","volume":4,"amount":136.8556,"timestamp":1790971805190,"change":0.7361,"changeRate":0.021515,"amplitude":0},"volumeRatio":5.104867656943041},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBIX\",,,,,undefined,":{"symbol":"XBIX","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":5.104867656943041,"shares":15000,"dividePrice":0,"high":34.99,"amplitude":0.022584,"preClose":34.3643,"low":34.2139,"week52Low":25.2639,"pbRate":"--","week52High":42.2188,"institutionHeld":0,"latestPrice":34.2139,"eps":0,"divideRate":0,"volume":15626,"delay":0,"ttmEps":0,"open":34.99,"prevYearClose":25.42,"prevWeekClose":34.6603,"prevMonthClose":35.9112,"prevQuarterClose":35.9112,"fiveDayClose":34.6603,"twentyDayClose":39.3866,"sixtyDayClose":40.627},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBIX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBIX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBIX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBIX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667671746","title":"ASX biotech expands diagnostics portfolio after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667671746","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667671746?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:00","pubTimestamp":1789488000,"startTime":"0","endTime":"0","summary":"Telix Pharmaceutical’s (ASX.TLX) Pixclara becomes the first positron emission tomography, or PET, imaging agent for glioma brain cancer to receive approval from the US Food and Drug Administration.Why","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/asx-biotech-expands-diagnostics-portfolio-after-fda-approval","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["IDNA","NVIB","PSCH","TECB","MEDI","BK4585","BMED","XBIX","IEIH","IYH","MRNX","MRNY","SYNB","GNMX","IBB","BBP","LABU","RSPH","BK4588","GDOC","TBXU","FRTY","PINK","LFSC","XLVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691804","title":"AdAlta takes ‘East to West’ CAR-T strategy and EW-001 data to U.S. investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691804?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:16","pubTimestamp":1789427795,"startTime":"0","endTime":"0","summary":"The latest update is out from AdAlta Ltd. ( ($AU:1AD) ). AdAlta Limited, an Australian clinical-stage biotech specialising in cellular immunotherap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adalta-takes-east-to-west-car-t-strategy-and-ew-001-data-to-u-s-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adalta-takes-east-to-west-car-t-strategy-and-ew-001-data-to-u-s-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667576635","title":"Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803","url":"https://stock-news.laohu8.com/highlight/detail?id=2667576635","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667576635?lang=en_us&edition=fundamental","pubTime":"2026-09-14 07:19","pubTimestamp":1789341541,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics Limited, a clinical-stage biotech in Melbourne, is developing pre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","IE00BD4GTV84.USD","BK4144","IE000WXP2NQ0.USD","IE00BD4GTW91.USD","BK4566","BBC","MLPX","NVIB","IE000SL1IH01.SGD","IE00BMG7P819.SGD","IE000HOSIQF4.USD","EINC","IE00BMG7P694.USD","IE00BMG7P702.HKD","IE00BD4GTT62.SGD","IE00BMG7P587.USD","TRP","IE00BMG7P926.USD","TPYP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635880","title":"Noxopharm Advances SOF-SKN into CLE Extension Study to Target Autoimmune Skin Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635880?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:56","pubTimestamp":1789340203,"startTime":"0","endTime":"0","summary":"Noxopharm Ltd. ( ($AU:NOX) ) has provided an update. Australian biotech Noxopharm is advancing its lead topical therapy SOF-SKN, developed from its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/noxopharm-advances-sof-skn-into-cle-extension-study-to-target-autoimmune-skin-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/noxopharm-advances-sof-skn-into-cle-extension-study-to-target-autoimmune-skin-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SOF","NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666111665","title":"The Race for the Next Big Weight-Loss Drug is On-and China Wants In","url":"https://stock-news.laohu8.com/highlight/detail?id=2666111665","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666111665?lang=en_us&edition=fundamental","pubTime":"2026-09-11 08:00","pubTimestamp":1789084800,"startTime":"0","endTime":"0","summary":"SHANGHAI-Chinese biotech companies, rapidly evolving from manufacturers of low-end generic drugs to serious competitors to American pharma giants, are training their sights on one of the most lucrativ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BMED","HYLG","NVIB","XBIX","MEDX","JDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666518847","title":"Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666518847?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:21","pubTimestamp":1789064460,"startTime":"0","endTime":"0","summary":"Investors poured fresh capital into applied AI and precision biotech this week, with Gimlet Labs raising $300M at a $3B valuation and Encoded Thera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/private-markets-gimlet-labs-encoded-therapeutics-secure-new-funding-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/private-markets-gimlet-labs-encoded-therapeutics-secure-new-funding-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TACU","VTHR","QTOC","AIPO","BK4007","LENZ","TSPA","ARTY","BK4539","CHAT","NVIB","BK4139","XBIX","CDIG","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665730023","title":"Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665730023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665730023?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:11","pubTimestamp":1788873063,"startTime":"0","endTime":"0","summary":"An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma has repositioned itself as a precision oncology-led biotech, m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-sharpened-strategy-centers-on-precision-oncology-and-targeted-rare-disease-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-sharpened-strategy-centers-on-precision-oncology-and-targeted-rare-disease-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","CANC","NVIB","CNCR","MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325354","title":"Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325354","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325354?lang=en_us&edition=fundamental","pubTime":"2026-09-05 05:18","pubTimestamp":1788556694,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. ( ($PLRZ) ) has provided an update. Polyrizon Ltd., a NASDAQ-listed development-stage biotech based in Raanana, Israel, is building ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/polyrizon-raises-4-million-in-registered-direct-offering-and-private-placement-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/polyrizon-raises-4-million-in-registered-direct-offering-and-private-placement-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","QID","QQQY","QQQ","NVIW.SI","MNQmain","TECS","IYW","QDTE","03086","NDX","NVIB","QQQA","QLD","XBIX","SQQQ","TQQY","QQQM","GPIQ","PSQ","QQQJ","FTEC","QYLG",".IXIC","ONEQ","TQQQ","JEPQ","QQQE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664808804","title":"VOOLT launches deeptech strategy with co‑investment in biotech firm Pikralida","url":"https://stock-news.laohu8.com/highlight/detail?id=2664808804","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664808804?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:21","pubTimestamp":1788445268,"startTime":"0","endTime":"0","summary":"VOOLT Spolka Akcyjna ( ($PL:VLT) ) just unveiled an update. VOOLT S.A. has made its first investment under a new deeptech‑focused strategy, committ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voolt-launches-deeptech-strategy-with-coinvestment-in-biotech-firm-pikralida?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voolt-launches-deeptech-strategy-with-coinvestment-in-biotech-firm-pikralida?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB","VLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664890506","title":"PegBio Partners SN BioScience to Advance Long-Acting Metabolic Peptide Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890506","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664890506?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:08","pubTimestamp":1788340086,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. Class H ( ($HK:2565) ) has shared an update. PegBio has entered a material transfer agreement with Korean biotech SN BioScience to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pegbio-partners-sn-bioscience-to-advance-long-acting-metabolic-peptide-candidates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pegbio-partners-sn-bioscience-to-advance-long-acting-metabolic-peptide-candidates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SN","NVIB","XBIX","LU0128526141.USD","LU0029874061.USD","LU2242644610.SGD","BK4191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664285768","title":"BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285768","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285768?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:26","pubTimestamp":1788272819,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical ( ($BMRN) ) just unveiled an announcement. BioMarin Pharmaceutical Inc. has completed the acquisition of Dutch biotech comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","BK4539","BK4007","LENZ","BK4581","XBI","BK4139","BK4588","NVIB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887912","title":"FutureChem sets final issue price for paid-in capital increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887912?lang=en_us&edition=fundamental","pubTime":"2026-09-01 10:46","pubTimestamp":1788230764,"startTime":"0","endTime":"0","summary":"FutureChem Co., Ltd. ( ($KR:220100) ) has issued an announcement. FutureChem Co., Ltd., a KOSDAQ-listed radiopharmaceutical and biotech company, ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883886","title":"Vogenx initiated with a Buy at Jones","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883886","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883886?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:15","pubTimestamp":1788207318,"startTime":"0","endTime":"0","summary":"Jones initiated coverage of Vogenx (VOGX) with a Buy rating and $55 price target Vogenx is a clinical-stage metabolic-focused biotech company, with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","VOGX","BK4007","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705792","title":"Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705792","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662705792?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:22","pubTimestamp":1787898153,"startTime":"0","endTime":"0","summary":"Repligen recently reported past second-quarter 2026 results that exceeded earnings and revenue expectations and raised its full-year 2026 guidance, highlighting broad year-over-year growth across filtration, chromatography, proteins, and process analytics.\nAn interesting detail is that this operational momentum, accompanied by higher full-year forecasts and rising analyst estimates, may reinforce perceptions of Repligen’s business strength across multiple bioprocessing franchises.\nWe’ll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgen/repligen/news/will-stronger-2026-guidance-and-broad-based-growth-change-re","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0757428866.USD","LU0205193047.USD","LU0012050646.USD","LU1815336091.USD","XBIX","LU0205194284.USD","RGEN","NVIB","BK4121","LU0106261612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662403754","title":"NeuroThera Labs Hires European IR Firm to Expand Investor Reach","url":"https://stock-news.laohu8.com/highlight/detail?id=2662403754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662403754?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:02","pubTimestamp":1787878968,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an announcement. NeuroThera Labs Inc., a clinical-stage biotech subsidiary of SciSparc Ltd. listed ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-hires-european-ir-firm-to-expand-investor-reach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPV","XBIX","NVIB","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662871430","title":"Oppenheimer biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2662871430","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662871430?lang=en_us&edition=fundamental","pubTime":"2026-08-28 02:00","pubTimestamp":1787853615,"startTime":"0","endTime":"0","summary":"Biotech Analysts, along with the Co-Director of Stanford Amyloid Cente, discuss the full results from AZN/IONS‘s CARDIO-TTRansform trial on an Anal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oppenheimer-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","BK4588","NVIB","BK4581","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662221703","title":"Natera and Angiex partner in tumor testing using Signatera","url":"https://stock-news.laohu8.com/highlight/detail?id=2662221703","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662221703?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:10","pubTimestamp":1787825446,"startTime":"0","endTime":"0","summary":"Natera (NTRA) announced a new Signatera collaboration with Angiex, a privately held biotech company developing a portfolio of Nuclear-Delivered Ant...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-and-angiex-partner-in-tumor-testing-using-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","NVIB","XBIX","LU2324357040.USD","LU0106261612.USD","LU2065731478.USD","LU2264538146.SGD","LU2065171402.SGD","LU0963586101.USD","LU0012050646.USD","HELX","LU0345770308.USD","LU0345770993.USD","LU1064131342.USD","BK4139","LU0053671581.USD","LU2065171311.SGD","LU2065169927.USD","NTRA","LU1988902786.USD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662747010","title":"Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2662747010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662747010?lang=en_us&edition=fundamental","pubTime":"2026-08-27 05:47","pubTimestamp":1787780836,"startTime":"0","endTime":"0","summary":"Immatics ( ($IMTX) ) just unveiled an announcement. Immatics N.V., a Nasdaq-listed biotech company headquartered in Houston and Tübingen, focuses o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immatics-raises-161-million-in-completed-equity-offering-to-advance-prame-cancer-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","XBIX","LCLG","REZ","BK4585","BK4588","NVIB","EQR","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760410","title":"4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760410","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662760410?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:13","pubTimestamp":1787724830,"startTime":"0","endTime":"0","summary":"4basebio UK Societas ( ($GB:4BB) ) has issued an update. 4basebio PLC, a UK-listed biotech focused on synthetic, cell-free DNA and mRNA for advance...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/4basebio-strikes-genezen-pact-to-advance-synthetic-dna-for-viral-vector-manufacturing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","XBIX","BK4139","DNA","BK4109","VAQC","BK4561","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662204407","title":"Syngenis banks R&D refund to fuel biotech build-out","url":"https://stock-news.laohu8.com/highlight/detail?id=2662204407","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662204407?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:06","pubTimestamp":1787584007,"startTime":"0","endTime":"0","summary":"Biotech hopeful Syngenis Labs has banked a $363,000 R&D tax refund atop a recent $4 million pre-IPO raise, adding non-dilutive firepower as it builds out its Australian RNA and DNA manufacturing platform.","market":"nz","thumbnail":"https://images.thewest.com.au/publication/C-22771960/cfe32dd8d5c27df108386c3ef5f67af0dd0eab91.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22771960/cfe32dd8d5c27df108386c3ef5f67af0dd0eab91.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/syngenis-banks-rd-refund-to-fuel-biotech-build-out-c-22771960","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/syngenis-banks-rd-refund-to-fuel-biotech-build-out-c-22771960","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["BK4590","XBIX","BMED","BK4144","GLP","NVIB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":65,"code":"91000000","status":"200"}]}}